Home
About Us
About Us

Beijing Northland Biotechnology Co., Ltd. is an innovative biopharmaceutical company specializing in the research, development, production, and sales of gene therapy drugs, recombinant protein drugs, and ophthalmic drugs.
News
R&D and Products
R&D and Products

Primarily dedicated to the research, development, and industrialization of novel bioengineered drugs in areas such as cardiovascular diseases, metabolic disorders, rare diseases, and ophthalmic diseases.
Investor Relations
Investor Relations

Guided by the principle of “Creating Value, Serving Health,” the company is committed to becoming an innovative biopharmaceutical enterprise, contributing to the advancement of China’s pharmaceutical industry and the well-being of humanity.
Our Businesses
- NL-PHARM
- Hounland
Our Businesses

Owns Beijing Northland Biopharmaceutical Co., Ltd. and Beijing Huons Pharmaceutical Co., Ltd., which are engaged in bioengineering drugs and ophthalmic products, respectively.

Language

NORTHLAND’s innovative drug, China’s first gene therapy for severe lower-limb ischemia—cedomine injection (Huasuo Ling®)—has been officially approved, filling a critical gap in clinical causal treatment.

发布时间：2026-05-29

On May 28, 2026, Seltoplasmid Injection (trade name: Huasuoling®), a Class 1 innovative therapeutic biologic developed independently by Beijing Northland Biotechnology Co., Ltd. (hereinafter referred to as “NORTHLAND,” stock code: 920047), was officially approved for marketing by the National Medical Products Administration, with approval number: S20260032. This drug is China’s first—and currently only—approved gene therapy for promoting angiogenesis. Employing an innovative “therapeutic angiogenesis” strategy, it will provide a completely new treatment option for Chinese patients with severe lower limb ischemia (CLI) who are unsuitable for revascularization surgery or whose surgical outcomes are suboptimal, thereby filling the gap in etiological treatment for CLI in China.

2026-01

The Phase III clinical trial results of Donaperminogene Seltoplasmid Injection—a gene therapy drug originally developed in China—were presented at LINC2026, a top international academic forum.

发布时间：2026-01-30

From January 27 to 30, 2026, the Leipzig Interventional Vascular Conference (LINC 2026)—renowned as the “global benchmark for vascular intervention therapy”—will be held in Leipzig, Germany. At the conference, Professor Di Xiao from the Department of Vascular Surgery at Peking Union Medical College Hospital, representing the research team, officially released the pivotal data from the Phase III clinical trial (HOPE CLTI-2 study) of “Sedominji Injection,” an innovative gene therapy drug independently developed by our company, for the treatment of chronic limb-threatening ischemia (CLTI) of the lower limbs. This marks the first time that a Chinese-originated gene therapy drug has presented large-scale clinical research findings on an internationally leading academic platform such as LINC.

2026-01

The holding subsidiary’s cyclosporine eye drops have been approved for clinical trials, accelerating its strategic transformation toward high-end products.

发布时间：2026-01-28

Recently, Huonland, a subsidiary of NORTHLAND Holdings, successfully passed the review by the National Medical Products Administration for its 0.05% cyclosporine eye drops (II), which were filed under Category 3 of chemical products, and received the "Drug Clinical Trial Approval Notice" (Notice No.: 2026LP00228). This marks another significant milestone in Huienland's strategic upgrade—from a generic drug manufacturer to a high-end ophthalmic formulation R&D enterprise.

2026-01

Party Day Activity

发布时间：2026-01-08

2026-01

Welcoming the New Year 2025

发布时间：2026-01-08

2026-01

Join the Huimai Forum

发布时间：2026-01-08

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Friendly Links: Baidu | NORTHLAND

Contact Information

Address: Room A406, Zhongguancun Biomedical Park, No. 5 Kaituo Road, Shangdi, Haidian District, Beijing

Hotline: +86 010-82890893

Email: northland@northland-bio.com

Website: www.northland-bio.com

Complaints Reporting Hotline: +86 010-82890893-8031

Complaints Reporting Email: pv@northland-bio.com

ADR information: Click to Download

Northland is an innovative biopharmaceutical company specializing in the R&D, manufacturing and sales of gene therapy drugs, recombinant protein drugs and ophthalmic medications.

Web site

NL-BIO

Scientific Research on Lower Limb Ischemia

NL003

Myocardial Infarction Scientific Research

NL005

Business license